Drugs / Berberine
last change 26 days ago re-read 9 days ago

Berberine

Traditional medicine (herbal / TCM) targets KCNH6, LDLR via inhibition

Developed for
Helicobacter pylori infectious disease · metabolic syndrome X · schizophrenia · type 2 diabetes mellitus · colorectal adenoma · hyperlipidemia · coronary artery disorder · diabetes mellitus
+21 more · dyspepsia · prediabetes syndrome · abdominal obesity-metabolic syndrome · gastritis · hypertensive disorder · NAFLD1 · obesity disorder · peptic ulcer disease · polycystic ovary syndrome · atherosclerotic cardiovascular disease · chronic endometritis · COVID-19 · diverticulitis · esophageal varices · gastric intestinal metaplasia · hyperglycemia · hyperlipidemia, combined, 2 · latent autoimmune diabetes in adults · lung adenocarcinoma · metabolic dysfunction-associated steatohepatitis · ulcerative colitis
Investigated by
Xijing Hospital of Digestive Diseases · Shanghai Jiao Tong University School of Medicine · Tianjin Anding Hospital · Xijing Hospital · China National Center for Cardiovascular Diseases · Heilongjiang University of Chinese Medicine
+48 more · Nanjing First Hospital, Nanjing Medical University · Peking Union Medical College Hospital · The University of Hong Kong · Beijing Tongren Hospital · Cardiomed LLC, Armenia · Center for New Medical Technologies, Novosibirsk, Russia · Chang'An Hospital · Chinese Medical Association · Chinese Society of Cardiology · Dr. Adi Lahat · EuroPharma, Inc. · Food and Health Bureau, Hong Kong · Fudan University · Fujian Cancer Hospital · Genertec Universal Xi'an Aero-Engine hospital (Xi' an) Co., Ltd · Guangdong Provincial People's Hospital · Hospital Civil de Guadalajara · Institute of Fine Organic Chemistry of the National Academy of Science, Armenia · Jin-Kui Yang · Jing-yuan Fang, MD, Ph. D · Jun Tao · Ministry of Science and Technology of the People´s Republic of China · National Cancer Institute (NCI) · National Institutes of Health (NIH) · Peking University People's Hospital · Phytomed AB, Sweden · S.LAB (SOLOWAYS) · Scientific Center of Drug and Medical Technologies Expertise of the Ministry of Health, Armenia · Second Affiliated Hospital of Xi'an Jiaotong University · Second Xiangya Hospital of Central South University · Shaanxi Aerospace Hospital · Shanghai Mental Health Center · Shanghai Municipal Science and Technology Commission · Shangluo Central Hospital · Tang Yida · The Affiliated Hospital of Hangzhou Normal University · The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Tianjin Second People's Hospital · University of Guadalajara · University of Roma La Sapienza · Wenzhou Medical University · Xi'an Central Hospital · Xi'an Gaoxin Hospital · Xin Gao · Xinjiang Medical University · Yan'an People's Hospital · Yan'an University Affiliated Hospital · Yu Chen

Trials 56

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials · 1 met primary
Phase 0 NCT05947370 Oct 2022 → Apr 2023 diabetes mellitus Beijing Tongren Hospital Completed No outcome recorded
Phase 0 NCT03972215 Oct 2019 → Jan 2020 diabetes mellitus Jin-Kui Yang Completed Met primary
Phase 12 trials
Phase 1 NCT04918667 Sep 2024 → Nov 2025 overdue — EuroPharma, Inc. Not yet recruiting No outcome recorded
Phase 1 NCT02365480 Jun 2016 → Feb 2018 ulcerative colitis National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT07180563 Mar 2025 → Nov 2026 expected chronic endometritis The Fourth Affiliated Hospital of Zhejiang University School of Medicine Recruiting No outcome recorded
Phase 1/2 NCT04434365 Jun → Nov 2019 coronary artery disorder Peking Union Medical College Hospital Unknown No outcome recorded
Phase 1/2 NCT00425009 Jan → Dec 2004 type 2 diabetes mellitus Shanghai Jiao Tong University School of Medicine Completed No outcome recorded
Phase 25 trials
Phase 2 NCT05596214 Aug 2022 → Sep 2024 diverticulitis Dr. Adi Lahat Unknown No outcome recorded
Phase 2 NCT03486496 Jun 2018 → Jun 2019 lung adenocarcinoma Fujian Cancer Hospital Unknown No outcome recorded
Phase 2 NCT03198572 Aug 2017 → Nov 2024 metabolic dysfunction-associated steatohepatitis Fudan University Terminated No outcome recorded Stop: Enrollment
Phase 2 NCT03909763 Jan 2016 → Dec 2020 — Peking University People's Hospital Unknown No outcome recorded
Phase 2 NCT00633282 Mar 2008 → Aug 2011 NAFLD1 Xin Gao Completed No outcome recorded
Phase 2/37 trials · 1 met primary
Phase 2/3 NCT06782646 Aug 2024 → Dec 2025 overdue hyperlipidemia The University of Hong Kong Enrolling by invitation No outcome recorded
Phase 2/3 NCT03770325 Apr 2019 → Nov 2020 — The University of Hong Kong Completed No outcome recorded
Phase 2/3 NCT03333265 Sep 2017 → Aug 2020 colorectal adenoma Xijing Hospital of Digestive Diseases Completed No outcome recorded
Phase 2/3 NCT03281096 Aug 2017 → Oct 2020 colorectal adenoma Xijing Hospital of Digestive Diseases Completed No outcome recorded
Phase 2/3 NCT02084004 Nov 2015 → Apr 2018 type 2 diabetes mellitus Xijing Hospital Withdrawn No outcome recorded
Phase 2/3 NCT02082756 Nov 2015 → Apr 2018 prediabetes syndrome Xijing Hospital Withdrawn No outcome recorded
Phase 2/3 NCT02226185 Nov 2014 → Dec 2018 colorectal adenoma Shanghai Jiao Tong University School of Medicine Completed Met primary
Phase 35 trials · 1 met primary
Phase 3 NCT04543643 Nov 2021 → Oct 2023 esophageal varices, hepatitis C induced liver cirrhosis Tianjin Second People's Hospital Unknown No outcome recorded
Phase 3 NCT04860063 Apr 2021 → Apr 2022 HIV infectious disease, glucose intolerance, hyperlipidemia, lipodystrophy +1 Hospital Civil de Guadalajara Unknown No outcome recorded
Phase 3 NCT02861261 Aug 2016 → Dec 2017 type 2 diabetes mellitus Shanghai Jiao Tong University School of Medicine Unknown Met primary
Phase 3 NCT02548832 Apr 2013 → Apr 2020 hyperlipidemia, combined, 2 University of Guadalajara Completed No outcome recorded
Phase 3 NCT00462046 Apr 2005 → Sep 2006 metabolic syndrome X, type 2 diabetes mellitus Shanghai Jiao Tong University School of Medicine Completed No outcome recorded
Phase 421 trials · 1 met primary · 1 missed
Phase 4 NCT07129460 Oct 2025 → Dec 2026 expected gastric intestinal metaplasia Xijing Hospital of Digestive Diseases Not yet recruiting No outcome recorded
Phase 4 NCT07306988 Apr 2025 → Jun 2026 overdue Helicobacter pylori infectious disease, metabolic syndrome X Nanjing First Hospital, Nanjing Medical University Recruiting No outcome recorded
Phase 4 NCT06514274 Sep 2024 → Apr 2025 Helicobacter pylori infectious disease, chronic gastritis Xijing Hospital of Digestive Diseases Completed No outcome recorded
Phase 4 NCT06603688 Nov 2023 → Nov 2024 Helicobacter pylori infectious disease, chronic gastritis Xijing Hospital of Digestive Diseases Unknown No outcome recorded
Phase 4 NCT05749874 Oct 2023 → Dec 2026 expected abdominal obesity-metabolic syndrome, atherosclerotic cardiovascular disease, hyperlipidemia, hypertensive disorder +1 China National Center for Cardiovascular Diseases Active not recruiting No outcome recorded
Phase 4 NCT05647915 Jul 2023 → Aug 2024 NAFLD1, abdominal obesity-metabolic syndrome, obesity disorder China National Center for Cardiovascular Diseases Completed Missed primary
Phase 4 NCT04698330 May 2022 → Dec 2025 overdue latent autoimmune diabetes in adults Second Xiangya Hospital of Central South University Not yet recruiting No outcome recorded
Phase 4 NCT05014334 Dec 2021 → Mar 2022 Helicobacter pylori infectious disease, chronic gastritis Xijing Hospital of Digestive Diseases Completed No outcome recorded
Phase 4 NCT03708549 Dec 2021 → Oct 2023 metabolic syndrome X, schizophrenia Tianjin Anding Hospital Unknown No outcome recorded
Phase 4 NCT05105321 Dec 2021 → Dec 2026 expected metabolic syndrome X Tang Yida Not yet recruiting No outcome recorded
Phase not applicable11 trials · 1 met primary
— NCT07519681 May → Sep 2026 overdue colorectal adenoma, colorectal cancer Jing-yuan Fang, MD, Ph. D Not yet recruiting No outcome recorded
— NCT06911983 Jul → Dec 2025 overdue type 2 diabetes mellitus S.LAB (SOLOWAYS) Not yet recruiting No outcome recorded
— NCT05720299 Mar → Jun 2025 prediabetes syndrome Yu Chen Completed No outcome recorded
— NCT07356765 Sep 2023 → Jan 2027 expected schizophrenia Tianjin Anding Hospital Enrolling by invitation No outcome recorded
— NCT07359209 Jul 2023 → Jan 2026 — Tianjin Anding Hospital Completed No outcome recorded
— NCT03330184 Oct 2015 → Apr 2018 — Xijing Hospital Completed Met primary
— NCT03251716 Jan 2015 → Oct 2017 metabolic syndrome X, schizophrenia Tianjin Anding Hospital Completed No outcome recorded
— NCT03548155 Jul 2014 → Dec 2015 schizophrenia Tianjin Anding Hospital Completed No outcome recorded
— NCT02936414 Jul 2014 → Aug 2015 schizophrenia Tianjin Anding Hospital Completed No outcome recorded
— NCT01138930 Jun 2010 → Jun 2013 obesity disorder, polycystic ovary syndrome Heilongjiang University of Chinese Medicine Unknown No outcome recorded
Comparator or background therapy4 trials
Phase 2/3 NCT02983188 Comparator Apr 2018 → Dec 2020 metabolic syndrome X, schizophrenia The University of Hong Kong Completed No outcome recorded
Phase 4 NCT02962245 Comparator Nov 2016 → Jan 2018 ulcerative colitis Xijing Hospital of Digestive Diseases Withdrawn No outcome recorded Stop: Business
Phase 4 NCT01649986 Comparator Jan 2014 → Dec 2015 hyperlipidemia University of Roma La Sapienza Unknown No outcome recorded
Phase 4 NCT02001883 Comparator Nov 2013 → Dec 2014 coronary artery disorder University of Roma La Sapienza Unknown No outcome recorded

Evidence & citations 27 cited values

Every value below carries the sentence it was read from. 66 sources stand behind the page.

FieldValueCited text
Known as Berberine “Berberine * Dose: 500 mg three times daily (1,500 mg/day total) * Formulation: standardized berberine HCl tablets * Duration: 12 weeks” NCT06911983 ↗
54

“nutraceutical combined pill (1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg).” NCT02001883 ↗

“os, 1 pill containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg, once daily, 1 year” NCT01490229 ↗

“1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg” NCT01649986 ↗

“oral administration of berberine hydrochloride tablets 100mg Tid per day” NCT07180563 ↗

NCT02082756 ↗

NCT02936414 ↗

NCT06514274 ↗

NCT00462046 ↗

NCT06782646 ↗

NCT05749874 ↗

Show 44 more sources

Known as BBR “This study is designed as a large-scale, randomized, placebo-controlled, rater-blinded trial to investigate whether berberine (BBR), a chemical compound, can safely and...” NCT07356765 ↗
8

“Our previous clinical trial demonstrated that berberine (BBR) hydrochloride might reduce the recurrence and canceration of colorectal adenoma (CRA).” PMID 37553874 ↗ Aug 2023

“Berberine (BBR) hydrochloride is an isoquinoline alkaloid (chemical formula: C20H18NO4) extracted from traditional Chinese herb Coptis chinensis.” NCT04790942 ↗

“Measures altering gut microbiota like oral intake of probiotics or berberine (BBR), a bacteriostatic agent, merit metabolic homoeostasis.” PMID 33024120 ↗ Oct 2020

“Berberine (BBR), a small alkaloid isolated from medicinal plants, has antidiabetic, anti-inflammatory, and antibacterial effects.” PMID 35784546 ↗ Jun 2022

“Berberine (BBR), an isoquinoline alkaloid derived from plants, is widely used as a nonprescription drug to treat diarrhea.” NCT03909763 ↗

“Here, we report the effects of its main active component, berberine (BBR), on stimulating insulin secretion.” PMID 34556670 ↗ Sep 2021

“Berberine (BBR) is the main active ingredient of the ancient Chinese herb medicine Coptis.” NCT05947370 ↗

“a botanic compound berberine (BBR) on NAFLD” PMID 26252777 ↗ Aug 2015

Known as Berbericine ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Known as Berberin ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Known as Berberine Chloride ClinicalTrials.gov intervention name — accepted as the source's own label NCT02365480 ↗
Known as berberine hydrochloride “berberine hydrochloride tablets (0.1g\*100 tablets/bottle, Shenyang First Pharmaceutical Co., Ltd., Northeast Pharmaceutical Group)” NCT07180563 ↗
7

“Patients in the berberine group received berberine hydrochloride tablets (100 mg/tablet), three tablets three times daily.” NCT07359209 ↗

“Berberine hydrochloride is a conventional component in Chinese medicine.” NCT02226185 ↗

“Drug: Berberine Hydrochloride group” NCT03330184 ↗

NCT03281096 ↗

NCT04790942 ↗

NCT03333265 ↗

NCT07519681 ↗

Known as Berberine hydrochloride tablet ("Sine Tianping") “Berberine hydrochloride tablet ("Sine Tianping")” NCT03281096 ↗
Known as BERBERINE SULFATE ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Known as Berberine sulfate (2:1) ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Known as Berberine sulfate anhydrous ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Known as Berberine sulphate ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Known as Berberinum ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Known as Berberone ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Known as Erben ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Known as GNF-Pf-4545 ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Known as Majarine ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Known as Neutral berberine sulfate ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Known as NSC-163088 ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Known as NSC-5355 ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Known as NSC-646666 ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Known as Thalsine ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Known as Umbellatin ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Known as Umbellatine ChEMBL registry synonym — accepted as the source's own label CHEMBL295124 ↗
Action Inhibit “BBR might inhibit V. parvula and further weaken the immunomodulatory effect of B cells induced by V. parvula, thereby blocking the development of colorectal tumors.” PMID 37553874 ↗ Aug 2023
Modality Traditional medicine (herbal / TCM) “Berberine is the main active component of Coptis chinensis French, which was used for thousands of years in China in the treatment of human diseases including diabetes.” NCT00425009 ↗